Molecular biology and gene therapy in gastroenterology and hepatology

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue 1, 1999, Pages 1-7

  Blum, Hubert E ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Antisense oligonucleotides; DNA vaccination; Gene correction; Interfering peptides or proteins; Ribozymes; Suicide genes

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DNA VACCINE; RIBOZYME;

CLINICAL MEDICINE; CLINICAL PRACTICE; GASTROENTEROLOGY; GASTROINTESTINAL DISEASE; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; GENETIC DISORDER; HUMAN; LIVER DISEASE; MOLECULAR BIOLOGY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SAFETY;

EID: 0032975077     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199901000-00001     Document Type: Review

References (100)

1. Anderson WF. Human gene therapy. Science 1992; 256:808-813.
2. Friedmann T. Progress toward human gene therapy. Science 1989; 244:1275-1281.
3. Gutierrez AA, Lemoine NR, Sikora K. Gene therapy for cancer. Lancet 1992; 339:715-721.
4. Miller AD. Human gene therapy comes of age. Nature 1992; 357:455-460.
5. Morgan RA, Anderson WF. Human gene therapy. Annu Rev Biochem 1993; 62:191-217.
6. Mulligan RC. The basic science of gene therapy. Science 1993; 260:926-932.
7. Rosenberg SA. Gene therapy for cancer. JAMA 1992; 268:2416-2419.
8. Sarver N, Cairns S. Ribozyme frans-splicing and RNA tagging: following the messenger. Nature Med 1996; 2:641-642.
9. Jones JT, Lee SW, Sullenger BA. Tagging ribozyme reaction sites to follow frans-splicing in mammalian cells. Nature Med 1996; 2:643-648.
10. Lan N, Howrey RP, Lee S-W, Smith CA, Sullenger BA. Ribozyme-mediated repair of sickle β-globin mRNAs in erythrocyte precursors. Science 1998; 280:1593-1596.
11. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann J-L, Klatzmann D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993; 90:7024-7028.
12. Helene C. Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides. Eur J Cancer 1991; 27:1466-1471.
13. Helene C, Toulme JJ. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1990; 1049:99-125.
14. Haseloff J, Gerlach WL. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 1988; 334:585-591.
15. Thompson JD, Macejak D, Couture L, Stinchcomb DT. Ribozymes in gene therapy. Nature Med 1995; 1:277-278.
16. Calabretta B. Inhibition of protooncogene expression by antisense oligode-oxynucleotides: biological and therapeutic implications. Cancer Res 1991; 51:4505-4510.
17. Tseng BY, Brown KD. Antisense oligonucleotide technology in the development of cancer therapeutics. Cancer Gene Ther 1994; 1:65-71.
18. Herschkowitz I. Functional inactivation of genes by dominant negative mutations. Nature 1987; 329:219-222.
19. Blau HM, Springer ML. Muscle mediated gene therapy. N Engl J Med 1995; 333:1554-1556.
20. McDonnell WM, Askari FK. DNA vaccines. N Engl J Med 1996; 334:42-45.
21. Pardoll DM, Beckerleg AM. Exposing the immunology of naked DNA vac-cines. Immunity 1995; 3:165-169.
22. Kumar V, Sercarz E. Genetic vaccination: the advantages of going naked. Nature Med 1996; 2:857-859.
23. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo Jr LD. DNA-based immunization by in vivo transfection of dendritic cells. Nature Med 1996; 2:1122-1128.
24. Conry RM, Widera G, Lobuglio AF, Fuller JT, Moore, SE, Barlow DL, et al. Selected strategies to augment polynucleotide immunization. Gene Ther 1996; 3:67-74.
25. Ciernik F, Berzofsky JA, Carbone DP. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J Immunol 1996; 156:2369-2375.
26. Barry MA, Lai WC, Johnston SA. Protection against mycoplasma infection using expression-library immunization. Nature 1995; 377:632-635.
27. Tascon RE, Colston MJ, Ragno S, Stavropoulos E, Gregory D, Lowrie DB. Vaccination against tuberculosis by DNA injection. Nature Med 1996; 2:888-892.
28. Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, Deck RR, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nature Med 1996; 2:893-898.
29. Ulmer JB, Donnelly SE, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745-1749.
30. Donnelly JJ, Friedman A, Martinez D, Montgomery DL, Shiver JW, Motzel SL, et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nature Med 1995; 1:583-587.
31. Justewicz DM, Webster RG. Long-term maintenance of B cell immunity to influenza virus hemagglutinin in mice following DNA-based immunization. Virology 1996; 224:10-17.
32. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991; 66:589-600.
33. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, et al. Identification of FAP locus genes from chromosome 5q21. Science 1991; 253:661-665.
34. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991; 253:665-669.
35. Powell SM, Petersen GM, Krush AJ, Booker S, Giardiello FM, et al. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 1993; 329:1982-1987.
36. Brown MS, Goldstein JL A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232:34-37.
37. Bilheimer DW, Goldstein JL, Grundy SM, Starzl TE. Liver transplantation to provide low density lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. N Engl J Med 1984; 311:1658-1664.
38. Hoeg JM, Starzl TE, Brewer HB. Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia. Am J Cardiol 1987; 59:705-707.
39. Grossman M, Raper SE, Kozarsky K, Stein EA, Engelhardt JF, Müller D, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nature Genet 1994; 6:335-341.
40. Grossman M, Rader DJ, Muller DWM, Kolansky DM, Kozarsky K, Clark III BJ, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nature Med 1995; 1:1148-1154.
41. Overturf K, Al-Dhalimy M, Tanguay R, Brantly M, Ou C-N, Finegold M, et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nature Genet 1996; 12:266-273
42. (a). Yoon K, Cole-Strauss A, Kmiec EB. Targeted gene correction of episomal DNA in mammalian cells mediated by a chimeric RNA-DNA oligonucleotide. Proc Natl Acad Sci USA 1996; 93:2071-2076
43. (b). Kren BT, Bandyopadhyay P, Steer CJ. In vivo site-directed mutagenesis of factor IX gene by chimeric RNA/DNA oligonucleotides. Nature Med 1998; 4:285-290
44. Kren BT, Bandyopadhyay P, Parashar B, Chowdhury NR, Chowdhury JR, Steer CJ. Site-specific correction of genetic diseases in liver resulting from single nucleotide mutations in genomic DNA. Hepatology 1998; 28 (suppl): 498A (d).
45. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-767.
46. Toribara NW, Sleisenger MH. Screening for colorectal cancer. N Engl J Med 1995; 332:861-867.
47. Kinzler KW, Vogelstein B. Gatekeepers and caretakers. Nature 1997; 386:761-763.
48. Howe JR, Roth S, Ringold JC, Summers RW, Järvinen HJ, Sistonen P, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 1998; 280:1086-1088.
49. Kinzler KW, Vogelstein B. Landscaping the cancer terrain. Science 1998; 280:1036-1037.
50. Sato Y, Koshita Y, Hirayama M, Matuyama T, Wakimoto H, Hamada H, et al. Augmented antitumor effects of killer cells induced by tumor necrosis factor gene-transduced autologous tumor cells from gastrointestinal cancer patients. Hum Gene Ther 1996; 7:1895-1905.
51. Kaneko S, Hallenbeck P, Kotani T, Nakabayashi H, McGarrity G, Tamaoki T, et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 1995; 55:5283-5287.
52. Schmidt M, Wels W. Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha. Br J Cancer 1996; 74:853-862.
53. Chatter JS, Johnson PR, Wong KK. Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated antisense vector. Science 1992; 258:1485-1488.
54. Trono D. Feinberg MB, Baltimore D. HIV-1 gag mutants can dominantly interfere with the replication of the wild type virus. Cell 1992; 59:113-120.
55. Wu GY, Wu CH. Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J Biol Chem 1992; 267:12436-12439.
56. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med 1996; 2:668-675.
57. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4:25-36.
58. von Weizsäcker F, Blum HE, Wands JR. Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template. Biochem Biophys Res Commun 1992; 189:743-748.
59. Beck J, Nassal M. Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells. Nucl Acids Res 1995; 23:4954-4962.
60. Lieber A, He C-Y, Polyak SJ, Gretch DR, Barr D, Kay MA. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J Virol 1996; 70:8782-8791.
61. Sakamoto N, Wu CH, Wu GY. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J Clin Invest 1 996; 98:2720-2728.
62. Welch PJ, Tritz R, Yei S, Leavitt M, Yu M, Barber J. A potential therapeutic application of hairpin ribozymes - in vitro and in vivo studies of gene therapy for hepatitis C virus infection. Gene Ther 1996; 3:994-1001.
63. Wagner RW. Gene inhibition using antisense oligodeoxynucleotides. Nature 1994; 372:333-335.
64. Branch AD. A hitchhiker's guide to antisense and nonantisense biochemical pathways. Hepatology 1996; 24:1517-1529.
65. Dougherty WG, Parks TD. Transgenes and gene suppression: telling us something new? Curr Opin Cell Biol 1995; 7:399-405.
66. Goodarzi G, Gross SC, Tewari A, Watabe K. Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen. J Gen Virol 1990; 71:3021-3025.
67. Blum HE, Galun E, Weizsäcker F. Wands JR. Inhibition of hepatitis B virus by antisense oligodeoxynucleotides. Lancet 1991; 337:1230.
68. Nakazono K, Ito Y, Wu CH, Wu GY. Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro. Hepatology 1996; 23:1297-1303.
69. Wakita T. Wands JR. Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence. J Biol Chem 1994; 269:14205-14210.
70. Mizutani T, Kato N, Hirota M, Sugiyama K, Murakami A, Shimotchno K. Inhibition of hepatitis C virus replication by antisense oligonucleotide in culture cells. Biochem Biophys Res Commun 1995; 212:906-911.
71. Alt M, Renz R, Hofschneider PH, Paumgartner G, Caselmann WH. Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology 1995; 22:707-717.
72. Seki M, Honda Y. Phosphorothioate antisense oligodeoxynucleotides capable of inhibiting hepatitis C virus gene expression: in vitro translation assay. J Biochem 1995; 118:1199-1204.
73. Hanecak R. Brown-Driver V, Fox MC, Azad RF, Furusako S, Nozaki C, et al. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J Virol 1996; 70:5203-5212.
74. Vidalin O. Major ME, Rayner B, Imbach JL, Trepo C, Inchauspe G. In vitro inhibition of hepatitis C virus gene expression by chemically modified antisense oligodeoxynucleotides. Antimicrob Agents Chemother 1996; 40:2337-2344.
75. Yao Z, Zhou Y, Feng X, Chen C, Guo J. In vivo inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides in athymic nude mice. J Viral Hepatitis 1996; 3:19-22.
76. Offensperger WB, Offensperger S, Walter E, Teubner K, Igloi G, Blum HE, et al. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J 1993; 12:1257-1262.
77. Bartholomew RM, Carmichael EP, Findeis MA, Wu CH, Wu GY. Targeted delivery of antisense DNA in woodchuck hepatitis virus-infected woodchucks. J Viral Hepatitis 1995; 2:273-278.
78. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249:505-510.
79. Baltimore D. Intracellular immunization. Nature 1988; 325:395-396.
80. Delaney MA, Goyal S, Seeger C. In: Viral Hepatitis and Liver Disease. Hollinger FB, Lemon SM and Margolis H (editors). Baltimore: Williams & Wilkins; 1991. pp. 667-668.
81. Scaglioni PP, Melegari M, Wands JR. Characterization of hepatitis B virus core mutants that inhibit viral replication. Virology 1994; 205:112-120.
82. von Weizsäcker F, Wieland S, Blum HE. Inhibition of viral replication by genetically engineered mutants of the duck hepatitis B virus core protein. Hepatology 1996; 24:294-299.
83. Scaglioni P, Melegari M, Takahashi M, Chowdhury JR, Wands J. Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology 1996; 24:1010-1017.
84. Scaglioni PP, Melegari M, Wands JR. Posttranscriptional regulation of hepatitis B virus replication by the precore protein. J Virol 1997; 71:345-353.
85. Buckwold VE, Xu Z, Chen M, Yen TSB, Ou J-H. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996; 70:5845-5851.
86. Guidotti LG, Matzke B, Pasquinelli C, Schoenberger JM, Rogler CE, Chisari FV. The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice. J Virol 1996; 70:7056-7061.
87. Davis HL, Michel ML, Whalen RG. DMA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol Genet 1993; 2:1847-1851.
88. Davis HL, McCluskie MJ, Gerin JL, Purcell RH. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci USA 1996; 93:7213-7218.
89. Davis HL, Mancini M, Michel ML, Whalen RG. DNA-mediated immunization to hepatitis B surface antigen - longevity of primary response and effect of boost. Vaccine 1996; 14:910-915.
90. Michel M-L, Davis HL, Schleef M, Mancini M, Tiollais P, Whalen RG. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci USA 1995; 92:5307-5311.
91. Schirmbeck R, Bohm W, Ando K, Chisari FV, Reimann J. Nucleic acid vaccination primes hepatitis B virus surface antigen specific cytotoxic T lymphocytes in nonresponder mice. J Virol 1995; 69:5929-5934.
92. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, et al. Development of a lipopeptide based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995; 95:341-349.
93. Kuhöber A, Pudollek HP, Reifenberg K, Chisari FV, Schlicht HJ, Reimann J, et al. DNA immunization induces antibody and cytotoxic T cell responses to hepatitis Score antigen in H-2b mice. J Immunol 1996; 156:3687-3695.
94. Davis HL, Schirmbeck R, Reimann J, Whalen RG. DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein. Hum Gene Ther 1995; 6:1447-1456.
95. Mancini M, Hadchouel M, Davis HL, Whalen RG, Tiollais P, Michel M-L. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci USA 1996; 93:12496-12501.
96. Lagging LM, Meyer K, Hoft D, Houghton M, Belshe RB, Ray R. Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J Virol 1995; 69:5859-5863.
97. Major ME, Vitvitski L, Mink MA, Schleef M, Whalen RG, Trepo C, et al. DNA based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol 1995; 69:5798-5805.
98. Chow Y-H, Huang W-L, Chi W-K, Chu Y-D, Tao M-H. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J Virol 1997; 71:169-178.
99. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995; 270:404-410.
100. Friedmann T. Human gene therapy - an immature genie, but certainly out of the bottle. Nature Med 1996; 2:144-147.